Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Pedersen and Maggie Fick COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk said on Wednesday it will sharpen its commercial ...

Novo Nordisk (NYSE: NVO) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials.

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

As announced July 29, Novo Nordisk NVO saw 18% sales growth and 40% operating profit growth at constant currencies in the ...

Novo Nordisk A/S (NYSE:NVO) is one of the top NYSE stocks with the highest upside potential. On August 5, UBS downgraded Novo ...